SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets USFDA’s final approval for Diltiazem Hydrochloride Tablets

11 Aug 2025 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg (USRLD: Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg). Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle. 

Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh. Diltiazem Hydrochloride Tablets had annual sales of $13.9 million in the United States (IQVIA MAT June 2025). The group now has 423 approvals and has so far filed around 483 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

931.80 8.70 (0.94%)
15-Apr-2026 11:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.10
Dr. Reddys Lab 1213.20
Cipla 1224.85
Zydus Lifesciences 931.80
Lupin 2345.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×